Navigation Links
Synthetic Biologics to Present at the 25th Annual ROTH Conference
Date:3/12/2013

ROCKVILLE, Md., March 12, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its Chief Executive Officer, Jeffrey Riley , will present at the 25th Annual ROTH Conference being held on March 17-20, 2013 at the Ritz-Carlton, Laguna Niguel in Dana Point, California. Mr. Riley is scheduled to present on Tuesday, March 19, 2013 at 1:30 p.m. (Pacific Time).

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the web at http://wsw.com/webcast/roth27/syn/. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' Chief Financial Officer, C. Evan Ballantyne , and its Executive Vice President, Research & Development, John Monahan , Ph.D., will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

About Synthetic Biologics, Inc.

Synthetic Biologics is a biotechnology company focused on the development of product candidates for serious infections and diseases. Synthetic Biologics is developing a biologic for the prevention of C. difficile infection, and a series of monoclonal antibodies for the treatment of serious infectious diseases, including pertussis and Acinetobacter. The Company is also developing a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and is designing a clinical development pathway for the treatment of amyotrophic lateral sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
2. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
3. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
4. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
5. The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
6. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
7. Synthetic Biologics Reports Second Quarter 2012 Financial Results
8. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
9. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
10. Biologics Research Promises to Bolster Future of Medicine
11. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
(Date:7/26/2017)... SINGAPORE , July 27, 2017  Radium Medical Aesthetics, a ... LASEMD, designed to delay aging by effectively addressing several skin conditions ... the skin to become rougher and more fragile. The skin becomes ... the unavoidable exposure to the harmful UV rays from the sun ... hyperpigmentation. ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 18, 2017 , ... “Steve the Snake”: an entertaining and moral-based short story ... of published author, Harold Flash Haskins Jr., a husband, father and grandfather who served ... , “I write moral-based short stories for children and teens. My goal is to ...
(Date:8/17/2017)... Waltham, Mass (PRWEB) , ... August 17, 2017 ... ... high use by health care organizations and considered extremely effective, very effective, or ... “Leading Physicians and Physician Leadership”. , NEJM Catalyst Insights Reports are based on ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... on September 19, 2017 for Anti-Infectives Rx. This off-the-record networking forum of the ... Center at Harvard Medical School. , Industry leaders and decision makers will discuss ...
(Date:8/17/2017)... ... , ... The line-up includes voices from all sectors of the dental technology ... a competitive market environment where Corporate Dentistry is making inroads. , ... practice.” says Daniel A. ‘Danny’ Bobrow, AIM Dental Marketing’s president, and Event Host. ...
(Date:8/17/2017)... ... August 17, 2017 , ... The 2017 Integrated Delivery Network ... to interact with their GPO and supplier partners. This year, Winifred Hayes, RN, ... Director of Clinical Value Analytics, have been invited to present “Episode-based Reimbursement and ...
Breaking Medicine News(10 mins):